Frankfurt am Main, Germany

Sven Ruf

USPTO Granted Patents = 23 

 

 

Average Co-Inventor Count = 7.5

ph-index = 3

Forward Citations = 43(Granted Patents)


Location History:

  • Flöersheim, DE (2004)
  • Florsheim, DE (2008 - 2009)
  • Floersheim, DE (2008 - 2010)
  • Flörsheim, DE (2010)
  • Mainz, DE (2010 - 2014)
  • Frankfurt-am-Main, DE (2013 - 2017)

Company Filing History:


Years Active: 2004-2017

Loading Chart...
Loading Chart...
Loading Chart...
23 patents (USPTO):

Title: Innovations and Contributions of Sven Ruf in the Pharmaceutical Field

Introduction

Sven Ruf, located in Frankfurt am Main, Germany, is a prolific inventor with 23 patents to his name. His work predominantly revolves around pharmaceutical innovations, aiming to develop compounds that combat serious health issues. With a keen focus on advancing medical science, he has made substantial contributions that are recognized within the industry.

Latest Patents

One of Sven Ruf's significant inventions involves the development of 3-heteroaroylamino-propionic acid derivatives. These compounds, classified under a specific formula I, hold promise as valuable pharmaceutical active compounds. They serve as inhibitors of the protease cathepsin A, which are crucial for treating diseases such as atherosclerosis, heart failure, renal diseases, liver diseases, and various inflammatory diseases. His patent also describes the processes for the synthesis of these compounds, their intended applications, and the pharmaceutical compositions that comprise them.

Career Highlights

Throughout his career, Sven Ruf has collaborated with notable companies such as Sanofi and Aventis Pharma S.A. His tenure at these organizations has enabled him to leverage his expertise in pharmaceutical sciences, leading to groundbreaking innovations that address significant health challenges.

Collaborations

Sven has collaborated with esteemed colleagues, including Thorsten Sadowski and Herman Schreuder. These collaborations have played a pivotal role in advancing his research and enhancing the efficacy of the compounds he has developed. Working together, they have contributed to a better understanding of pharmaceutical development and applications.

Conclusion

Sven Ruf continues to be a valuable asset to the pharmaceutical innovation landscape. His extensive portfolio of patents, particularly in the area of therapeutic compounds, demonstrates his commitment to improving healthcare solutions. As he forges ahead in his research, the impact of his inventions is likely to resonate within both the scientific community and the broader healthcare industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…